NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 177 filers reported holding NEVRO CORP in Q1 2019. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $372,632 | -42.7% | 14,659 | -18.5% | 0.05% | -42.0% |
| Q1 2023 | $650,339 | -70.5% | 17,990 | -67.7% | 0.09% | -75.4% |
| Q4 2022 | $2,206,314 | +43.5% | 55,715 | +68.9% | 0.36% | +53.2% |
| Q3 2022 | $1,537,000 | -7.4% | 32,987 | -12.8% | 0.23% | +59.6% |
| Q2 2022 | $1,659,000 | +538.1% | 37,842 | +953.8% | 0.15% | +563.6% |
| Q1 2022 | $260,000 | -76.4% | 3,591 | -43.7% | 0.02% | -70.7% |
| Q4 2020 | $1,104,000 | -70.9% | 6,375 | -89.5% | 0.08% | -65.1% |
| Q1 2019 | $3,796,000 | +12.0% | 60,729 | -30.3% | 0.22% | +13.8% |
| Q4 2018 | $3,388,000 | +20.3% | 87,112 | +76.3% | 0.19% | +61.5% |
| Q3 2018 | $2,816,000 | -32.8% | 49,402 | -5.9% | 0.12% | -26.4% |
| Q2 2018 | $4,192,000 | +136.4% | 52,500 | +59.1% | 0.16% | +245.7% |
| Q2 2015 | $1,773,000 | +103.3% | 32,989 | +81.2% | 0.05% | +109.1% |
| Q1 2015 | $872,000 | – | 18,203 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |